drugset / Trial / NCT00206947
The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
Phase 2
Terminated
50 enrolled
Birte Glenthoj
Glostrup University Hospital, Copenhagen · collabPfizer · collabRigshospitalet, Denmark · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The present study will specify and delineate the separate components of cognitive deficits and examine the effects of adjunctive cholinergic augmentation on these cognitive deficits as well as psychopathology in schizophrenic patients treated with an antipsychotic compound with no aberrant binding affinity for the cholinergic receptor system. The hypothesis is that cholinergic augmentation using donepezil will improve cognitive deficits, sensory gating deficits, and psychopathology in schizophrenic patients treated with an atypical antipsychotic (ziprasidone).
Timeline
- Start
- 2002-12
- Primary completion
- 2005-01
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Donepezil | Small molecule | 5 mg | — |
| Comparator | Donepezil | Small molecule | 10 mg | — |